Chemotherapy Safe After Radium-223 for Men With mCRPC
The explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.
Prostate Cancer Study Shows Hypofractionation Comparable to Standard Radiation in Low-risk Patients
Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.
Shorter Radiation Technique Comparable to Standard Radiation for Low-Risk Breast Cancer
A phase III study shows noninferiority of accelerated partial breast irradiation as compared to conventional whole breast irradiation.
Hypofractionated Radiotherapy May be Viable in Intermediate- and High-Risk Prostate Cancer
Hypofractionation, known as delivering higher doses of radiation in fewer fractions, appears to be feasible and non-inferior compared with conventional fractionated radiotherapy.
Coordination of Care Based on Patient-Reported Outcomes Improves End-of-Life Care and Lowers Costs
Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.
Tasquinimod Discontinuation in mCRPC Highlights Need for Better Clinical Trial Design
Tasquinimod demonstrated promise in phase II trials but failed to improve overall survival in a phase III trial in treatment-naive metastatic castration-resistant prostate cancer; some experts believe this failure highlights the need for more intelligent clinical trial designs in prostate cancer.
Massive Trial in Prostate Cancer Supports Accelerated Hypofractionated Radiotherapy
Accelerated hypofractionated radiotherapy using a schedule of 60 Gy in 20 fractions of 3 Gy delivered in 4 weeks was found to be comparable to the conventional schedule of 74 Gy/37 of 2 GY delivered in 7.2 weeks in patients with localized prostate cancer taking androgen deprivation therapy.
Chemotherapy After Radium-223 Safe in Metastatic Castration-Resistant Prostate Cancer
A subanalysis of the ALSYMPCA trial suggests that chemotherapy can be safely administered after treatment with radium-223 in patients with metastatic CRPC and bone metastasis.
Breast/Ovarian Cancer Multigene Panel Testing Changes Clinical Management
Evidence is mounting for multigene panel testing in women with suspected familial breast and/or ovarian cancer.
TRINOVA-1 Trial: Promise for Trebananib in Ovarian Cancer
Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial.
Enzalutamide Delays First SRE, Improves Pain and QoL in Patients With Metastatic Prostate Cancer
An analysis of the phase III AFFIRM trial showed that enzalutamide significantly delayed the time to first skeletal-related event and significantly improved pain and quality of life compared with placebo in men with mCRPC who had received prior docetaxel.
2 Clarke Drive Cranbury, NJ 08512